Quantcast
Last updated on April 24, 2014 at 10:35 EDT

Latest tumor Stories

2013-11-01 08:26:52

Novel hydrogel acts as drug delivery depot that reduces tumor size in fewer treatments than traditional therapies SAN JOSE, Calif., Nov. 1, 2013 /PRNewswire/ -- Today, scientists from IBM (NYSE: IBM) and Singapore's Institute of Bioengineering and Nanotechnology (IBN) published a breakthrough drug-delivery technique, demonstrating the first biodegradable, biocompatible and non-toxic hydrogel that can deliver treatment more efficiently to people fighting breast cancer. (Logo:...

2013-10-27 23:00:55

May Be Able to Recreate Conditions That Keep Cancer Cells from Growing after They Have Spread New York, NY (PRWEB) October 27, 2013 Oncologists have long puzzled over the fact that after cancer treatment, single cancer cells that are dispersed throughout the body – so-called disseminated tumor cells – are quick to grow and form secondary tumors called metastases in certain organs, while in other organs they metastasize more slowly, sometimes decades later. Such is the case with head...

2013-10-21 13:17:16

LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October...

2013-10-21 12:27:56

3-V's Small Molecule Tumor Metabolism Inhibitor Demonstrates Single-Agent Activity; Halts Tumor Growth and Induces Tumor Regression MENLO PARK, Calif., Oct. 21, 2013 /PRNewswire/ -- 3-V Biosciences, Inc., a biopharmaceutical company developing therapeutics that modulate key host-cell pathways resulting in death of tumor cells or virally-infected cells, today presented positive data from preclinical studies of the company's novel fatty acid synthase (FASN) inhibitors. (Logo:...

2013-10-21 04:20:56

-- Findings Suggest New Class of Anti-Cancer Agents with Novel Mechanism for Tumor Cell Killing -- SEATTLE, Oct. 21, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the presentation of findings from a preclinical study of PIXUVRI(®) (pixantrone) that suggest its mechanism of inducing tumor cell death is novel and distinct from that of anthracyclines such as doxorubicin. PIXUVRI is a first-in-class aza-anthracenedione with unique structural...

2013-10-17 12:29:39

ANN ARBOR, Mich. and FREIBURG, Germany, Oct. 17, 2013 /PRNewswire/ -- Molecular Imaging, Inc. ("Molecular Imaging") and Oncotest GmbH ("Oncotest") announced today that they have entered into a collaboration and co-promotion agreement to apply Molecular Imaging's experience and expertise in in-vivo pre-clinical Imaging to the pioneering Patient Derived Xenograft (PDX) work of Oncotest. Under the terms of the agreement both companies will promote the ability to perform PDX pharmacology...

2013-10-16 09:21:11

Parvoviruses cause no harm in humans, but they can attack and kill cancer cells. Since 1992, scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have been studying these viruses with the aim of developing a viral therapy to treat glioblastomas, a type of aggressively growing brain cancer. A clinical trial has been conducted since 2011 at the Heidelberg University Neurosurgery Hospital to test the safety of treating cancer patients with the parvovirus H-1....

Red Wine Compound Helps Kill Cancer Cells
2013-10-14 10:50:04

[ Watch the Video: Red Wine Scores More Health Points ] Brett Smith for redOrbit.com - Your Universe Online Previous research has linked red wine to numerous health benefits, and a new study from the University of Missouri has found that a compound in the beverage can be used to boost the effectiveness of radiation-based cancer therapy. In the study, the red-wine compound resveratrol was used to treat melanoma cells, resulting in 44 percent of the tumor cells being killed. When the...

2013-10-09 08:27:22

Key components include an upgraded online physician portal, simplified genomic profile and newly-added biomarkers to support more informed therapeutic selections IRVING, Texas, Oct. 9, 2013 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, today launched significant enhancements to its Molecular Intelligence(TM) tumor profiling service. These enhancements include significant updates to MI Portal(TM), the...

2013-10-09 04:21:07

HAMBURG, Germany, October 9, 2013 /PRNewswire/ -- Sysmex Inostics, a subsidiary of Sysmex Corporation, today announced a master collaboration agreement with Bayer HealthCare for the development of companion diagnostics for targeted cancer therapies. The partnership pairs Sysmex Inostics' innovative blood-based companion diagnostic solutions with targeted anti-cancer agents developed by Bayer. "We are pleased to partner with Bayer HealthCare, a global company with an...